Transgene (XPAR:TNG) COGS-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Transgene COGS-to-Revenue?

Transgene's Cost of Goods Sold for the six months ended in Dec. 2024 was €0.00 Mil. Its Revenue for the six months ended in Dec. 2024 was €0.28 Mil.

Transgene's COGS to Revenue for the six months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Transgene's Gross Margin % for the six months ended in Dec. 2024 was N/A%.

Transgene COGS-to-Revenue Historical Data

The historical data trend for Transgene's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene COGS-to-Revenue Chart

Transgene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

Transgene Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Transgene COGS-to-Revenue Calculation

Transgene's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.307
	=	0.00

Transgene's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.284
	=	0.00

Transgene (XPAR:TNG) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Transgene's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.284
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Transgene COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Transgene's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

TRGNF:USA 0OCQ:UK TGNA:Germany

Address

400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.

Transgene Headlines

No Headlines